GHIT Fund Global Health Innovative Technology Fund

Investment

Investment Overview

Investment to Date

Since 2013

Breakdown

Disease
Total : 1000
（USD 1.00 = JPY 100）
Malaria $5,356,668,398 (40.6%)
Tuberculosis $5,356,668,398 (40.6%)
NTDs $5,356,668,398 (40.6%)
Intervention
Total : 1000
（USD 1.00 = JPY 100）
Drugs $5,356,668,398 (40.6%)
Vaccines $5,356,668,398 (40.6%)
Diagnostics $5,356,668,398 (40.6%)
Development
Stage
Total : 1000
（USD 1.00 = JPY 100）
Discovery $5,356,668,398 (40.6%)
Preclinical $5,356,668,398 (40.6%)
Clinical $5,356,668,398 (40.6%)

As of 2020.3.31

GHIT invests using Japanese yen. US dollar amounts represent conversions from Japanese yen, solely for the reader’s convenience, at JPY 100 = USD 1.

Every project is counted as a single investment, even if it has received multiple rounds of GHIT funding.

Due to rounding, total percentages under each category may not add up precisely to 100.
For projects that span across multiple GHIT investment platforms (i.e., programs that transition from one platform to the other), the total investment amount is shown based on the project's most current development status.

Find an Investment​

Check All Clear All

Each awarded project is listed once, regardless of whether it has received multiple investments from GHIT.
Development stage categories are as follows:

Drugs and Vaccines
Discovery: From Target Research to Hit-to-Lead ｜ Preclinical: Preclinical Development｜ Clinical: From Phase I to Registration

Diagnostics
Discovery: Target Research｜Preclinical: Product Design｜Clinical: From Product Development to Registration

Create Excel File
 
Development Stage Current Stage Disease Intervention RFP Year Status Project Partner Awarded Amount Details
Discovery Drug Hit Identification Malaria Drug 2013 COMPLETE Screening Program Eisai Co., Ltd.,Medicines for Malaria Venture (MMV) $104,264 Details
Discovery Drug Hit Identification Malaria Drug 2013 COMPLETE Screening Program Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV) $73,940 Details
Discovery Drug Hit Identification Malaria Drug 2013 COMPLETE Screening Program Kitasato Institute,Medicines for Malaria Venture (MMV) $570 Details
Discovery Drug Hit Identification Malaria Drug 2013 TERMINATED Screening Program Daiichi Sankyo, Inc.,Medicines for Malaria Venture (MMV) $241,372 Details
Discovery Drug Hit Identification Malaria Drug 2013 TERMINATED Screening Program Institute of Microbial Chemistry,Medicines for Malaria Venture (MMV) $11,286 Details
Discovery Drug Hit Identification Malaria Drug 2014 COMPLETE Screening Program Mitsubishi Tanabe Pharma,Medicines for Malaria Venture (MMV) $186,420 Details
Discovery Drug Hit Identification Malaria Drug 2014 COMPLETE Screening Program Sumitomo Dainippon Pharma Co., Ltd.,Medicines for Malaria Venture (MMV) $137,883 Details
Discovery Drug Lead Identification Malaria Drug 2014 COMPLETE Design and Cost-effective de novo Synthesis of Aza-artemisinins Kitasato Institute,Medicines for Malaria Venture (MMV),Hokkaido University $60,000 Details
Discovery Drug Lead Identification Malaria Drug 2014 TERMINATED Identification of lead compounds for anti-Malarial agent Daiichi Sankyo, Inc.,Medicines for Malaria Venture (MMV) $636,941 Details
Discovery Drug Hit Identification Malaria Drug 2015 ACTIVE Screening Program Daiichi Sankyo RD Novare Co., Ltd.,Medicines for Malaria Venture (MMV) $150,000 Details
Discovery Drug Lead Identification Malaria Drug 2015 COMPLETE Hit-to-Lead Discovery for New Anti-malarials in Collaboration between MMV and Eisai Eisai Co., Ltd.,Medicines for Malaria Venture (MMV) $779,760 Details
Discovery Drug Lead Identification Malaria Drug 2015 COMPLETE Antimalarial hits from whole cell screening Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV) $764,033 Details
Discovery Drug Target Validation Malaria Drug 2015 COMPLETE Proteasome inhibitors as new potent resistance-­reversing antimalarials Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV),The University of Melbourne $297,133 Details
Discovery Drug Hit Identification Malaria Drug 2015 COMPLETE Screening Program Op Bio Factory Co., Ltd.,Medicines for Malaria Venture (MMV) $68,400 Details
Discovery Drug Lead Identification Malaria Drug 2016 COMPLETE New Hit-to-Lead Activity for New Anti-Malarias between MMV and Eisai Eisai Co., Ltd.,Medicines for Malaria Venture (MMV) $750,000 Details
Discovery Drug Lead Identification Malaria Drug 2016 COMPLETE Mitsubishi Tanabe malaria Hit-to-Lead Mitsubishi Tanabe Pharma,Medicines for Malaria Venture (MMV) $618,222 Details
Discovery Drug Lead Identification Malaria Drug 2016 COMPLETE New Hit-to-Lead Activity for New Anti-Malarias between MMV and Takeda Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV) $483,360 Details
Discovery Drug Hit Identification Malaria Drug 2017 ACTIVE Screening Program Astellas Pharma Inc.,Medicines for Malaria Venture (MMV) $65,836 Details
Discovery Drug Lead Identification Malaria Drug 2017 COMPLETE HTL for selective Plasmodium proteasome inhibitors as new potent resistance-reversing antimalarials Takeda Pharmaceutical Company Limited,The University of Melbourne’s Bio21 Molecular Science and Biotechnology Institute,Medicines for Malaria Venture (MMV) $461,245 Details
Discovery Drug Lead Identification Malaria Drug 2017 COMPLETE New Hit-to-Lead Activity for New Anti-Malaria drugs between MMV and Sumitomo Dainippon Pharma Sumitomo Dainippon Pharma Co., Ltd.,Medicines for Malaria Venture (MMV) $445,500 Details
Discovery Drug Hit Identification Malaria Drug 2017 COMPLETE Screening Program Eisai Co., Ltd.,Medicines for Malaria Venture (MMV) $49,500 Details
Discovery Drug Lead Identification Malaria Drug 2018 ACTIVE New Hit-to-Lead Activity for New Anti-Malarials between MMV and Takeda Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV) $528,000 Details
Discovery Drug Hit Identification Malaria Drug 2018 ACTIVE Screening Program University of Tokyo,Medicines for Malaria Venture (MMV) $150,000 Details
Discovery Drug Lead Identification Malaria Drug 2019 ACTIVE Development of nucleoside sulfamates as novel antimalarials Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV),The University of Melbourne’s Bio21 Molecular Science and Biotechnology Institute $1,016,129 Details
Discovery Drug Lead Identification Malaria Drug 2019 ACTIVE Proteasome inhibitors as new potent antimalarials Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV),The University of Melbourne’s Bio21 Molecular Science and Biotechnology Institute $526,140 Details
Discovery Drug Hit Identification Malaria Drug 2019 ACTIVE Screening project between Takeda and MMV Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV) $41,962 Details
Discovery Vaccine Technology Platform Identification Malaria Vaccine 2013 COMPLETE Accelerating Development of Vaccines for Malaria Elimination Using a Novel Clinical Target Validation Approach CellFree Sciences Co. Ltd.,Ehime University,PATH Malaria Vaccine Initiative $591,396 Details
Discovery Vaccine Technology Platform Identification Malaria Vaccine 2014 COMPLETE Accelerating Development of Transmission-Blocking Vaccines for Malaria Elimination Using a Novel Vaccine Candidate Ehime University,PATH Malaria Vaccine Initiative $766,098 Details
Discovery Vaccine Antigen Identification Malaria Vaccine 2016 COMPLETE A Vaccine to Block Malaria Transmission: Pfs230 Antigen Design and Display Ehime University,PATH Malaria Vaccine Initiative $595,650 Details
Discovery Vaccine Antigen Identification Malaria Vaccine 2017 ACTIVE Identification of Vaccine Targets that Will Block the Interaction of Plasmodium falciparum Malaria Parasites with a Complement Regulator Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Antigen Discovery, Inc.,The Pennsylvania State University $881,900 Details
Discovery Vaccine Antigen Identification Malaria Vaccine 2018 ACTIVE Further development of a new asexual blood-stage malaria vaccine candidate Ehime University,iBET,European Vaccine Initiative (EVI) $930,571 Details
Discovery Vaccine Antigen Identification Malaria Vaccine 2019 ACTIVE Co-delivery of Pfs230C1 and CSP with CoPoP, a versatile, potent liposomal adjuvant system for multistage malaria vaccine Ehime University,University at Buffalo, The State University of New York,PATH Malaria Vaccine Initiative $972,951 Details
Discovery Vaccine Technology Platform Identification Malaria Vaccine 2019 ACTIVE Development of a novel Pvs25 nucleoside-modified mRNA vaccine that induces potent and long-lasting transmission blocking immunity Ehime University,University of Pennsylvania,Mahidol University $960,771 Details
Discovery Vaccine Vaccine Concept Development Malaria Vaccine 2019 ACTIVE Made-in-Japan next-generation vaccine platform effective for multistage Plasmodium for infants Hokkaido University,Jichi Medical University,Toyama University,University of Cambridge,Kanazawa University $526,900 Details
Discovery Diagnostic Technical Feasibility Malaria Diagnostic 2015 COMPLETE Development of serological biomarkers as indicators of recent and asymptomatic infections for innovative tools to accelerate malaria elimination CellFree Sciences Co. Ltd.,Foundation for Innovative New Diagnostics (FIND),Proteo-Science Centre, Ehime University,The Walter and Eliza Hall Institute of Medical Research $993,030 Details
Discovery Diagnostic Concept Development Malaria Diagnostic 2017 ACTIVE Towards rapid diagnosis of Plasmodium vivax malaria hypnozoite infection National Institute of Technology, Kumamoto College,Biomedical Primate Research Centre,Institute of Tropical Medicine (NEKKEN) Nagasaki University $728,830 Details
Discovery Drug Hit Identification Tuberculosis Drug 2013 COMPLETE Screening Program SHIONOGI & CO., LTD.,The Global Alliance for TB Drug Development $105,450 Details
Discovery Drug Hit Identification Tuberculosis Drug 2013 COMPLETE Screening Program Takeda Pharmaceutical Company Limited,The Global Alliance for TB Drug Development $55,550 Details
Discovery Drug Hit Identification Tuberculosis Drug 2013 TERMINATED Screening Program Daiichi Sankyo, Inc.,The Global Alliance for TB Drug Development $135,300 Details
Discovery Drug Hit Identification Tuberculosis Drug 2014 COMPLETE Screening Program Daiichi Sankyo RD Novare Co., Ltd.,The Global Alliance for TB Drug Development $150,000 Details
Discovery Drug Hit Identification Tuberculosis Drug 2014 TERMINATED Screening Program Op Bio Factory Co., Ltd.,The Global Alliance for TB Drug Development $150,000 Details
Discovery Drug Lead Identification Tuberculosis Drug 2015 COMPLETE Hit-to-Lead Development of anti-TB Phenotypic Screening Hits The Research Institute of Tuberculosis, Japan Anti-tuberculosis Association,The Global Alliance for TB Drug Development,SHIONOGI & CO., LTD. $999,720 Details
Discovery Drug Lead Identification Tuberculosis Drug 2015 COMPLETE Development of Phenotypic Screening Hits against Mycobacterium tuberculosis Takeda Pharmaceutical Company Limited,The Global Alliance for TB Drug Development $792,165 Details
Discovery Drug Hit Identification Tuberculosis Drug 2015 COMPLETE Screening Program Chugai Pharmaceutical Co., Ltd.,The Global Alliance for TB Drug Development $150,000 Details
Discovery Drug Hit Identification Tuberculosis Drug 2015 COMPLETE Screening Program Toyama Prefectural University,The Global Alliance for TB Drug Development,HYPHAGENESIS INC. $150,000 Details
Discovery Drug Hit Identification Tuberculosis Drug 2015 COMPLETE Screening Program Mitsubishi Tanabe Pharma,The Global Alliance for TB Drug Development $132,000 Details
Discovery Drug Hit Identification Tuberculosis Drug 2015 COMPLETE Screening Program Sumitomo Dainippon Pharma Co., Ltd.,The Global Alliance for TB Drug Development $79,200 Details
Discovery Drug Lead Identification Tuberculosis Drug 2015 TERMINATED Identification of lead compounds as novel anti‐TB agents Daiichi Sankyo, Inc.,The Global Alliance for TB Drug Development $908,231 Details
Discovery Drug Target Validation Tuberculosis Drug 2016 COMPLETE Host-directed drug targeting against tuberculosis RIKEN,International Centre for Genetic Engineering and Biotechnology $204,990 Details
Discovery Drug Hit Identification Tuberculosis Drug 2017 ACTIVE Screening Program Astellas Pharma Inc.,The Global Alliance for TB Drug Development $99,986 Details
Discovery Drug Lead Identification Tuberculosis Drug 2018 ACTIVE Hit-to-Lead Development of Novel anti-TB Natural Products Daiichi Sankyo RD Novare Co., Ltd.,The Global Alliance for TB Drug Development $1,192,440 Details
Discovery Drug Hit Identification Tuberculosis Drug 2018 ACTIVE Screening Program Fujifilm Corporation ,The Global Alliance for TB Drug Development $110,000 Details
Discovery Drug Lead Identification Tuberculosis Drug 2019 ACTIVE Hit-to-Lead Development of Phenotypic and Mechanism-based Screen Hits Takeda Pharmaceutical Company Limited,The Global Alliance for TB Drug Development $1,112,058 Details
Discovery Drug Lead Identification Tuberculosis Drug 2019 ACTIVE Hit-to-Lead Development of Phenotypic Screening Hits Chugai Pharmaceutical Co., Ltd.,The Global Alliance for TB Drug Development $953,159 Details
Discovery Vaccine Vaccine Concept Development Tuberculosis Vaccine 2016 COMPLETE Development of a new mucosal vaccine for Tuberculosis using antibody engineering University of Tokyo,Universidad de Concepcion,Instituto de Nutricion “Salvador Zubiran”,Universiti Sains Malaysia $373,561 Details
Discovery Diagnostic Concept Development Tuberculosis Diagnostic 2018 ACTIVE Development of LFA platform for improving sensitivity of Point-of-Care assays for infectious disease with main focus on Tuberculosis and Malaria. Asahi Kasei Corporation,Biopromic AB $1,000,000 Details
Discovery Drug Lead Identification NTD (Chagas disease) Drug 2013 COMPLETE Optimization of Diversity-Oriented Synthesis (DOS)-derived trypanocidal small molecule ML341 towards investigational new drug status for Chagas disease Eisai Co., Ltd.,Broad Institute $500,000 Details
Discovery Drug Hit Identification NTD (Chagas disease / Leishmaniasis) Drug 2013 COMPLETE Screening Program Eisai Co., Ltd.,Drugs for Neglected Diseases initiative $75,582 Details
Discovery Drug Hit Identification NTD (Chagas disease / Leishmaniasis) Drug 2013 COMPLETE Screening Program Takeda Pharmaceutical Company Limited,Drugs for Neglected Diseases initiative $75,582 Details
Discovery Drug Hit Identification NTD (Chagas disease / Leishmaniasis) Drug 2013 COMPLETE Screening Program Kitasato Institute,Drugs for Neglected Diseases initiative $0 Details
Discovery Drug Hit Identification NTD (Chagas disease / Leishmaniasis) Drug 2013 TERMINATED Screening Program Institute of Microbial Chemistry,Drugs for Neglected Diseases initiative $7,558 Details
Discovery Drug Lead Identification NTD (Chagas disease / Leishmaniasis) Drug 2014 COMPLETE Neglected Tropical Diseases Drug Discovery Booster Eisai Co., Ltd.,SHIONOGI & CO., LTD.,Takeda Pharmaceutical Company Limited,Drugs for Neglected Diseases initiative $795,437 Details
Discovery Drug Hit Identification NTD (Leishmaniasis) Drug 2015 ACTIVE Screening Program Eisai Co., Ltd.,Drugs for Neglected Diseases initiative $31,000 Details
Discovery Drug Hit Identification NTD (Chagas disease) Drug 2015 COMPLETE Screening Program Daiichi Sankyo, Inc.,Drugs for Neglected Diseases initiative $210,050 Details
Discovery Drug Target Validation NTD (Chagas disease / Leishmaniasis) Drug 2016 COMPLETE Targeting bromodomains for novel anti-parasitic mechanisms of action for malaria, Chagas disease, leishmaniasis and cryptosporidiosis RIKEN,McGill University ,Medicines for Malaria Venture (MMV),Structural Genomics Consortium at University of Toronto,The University of Melbourne,Drugs for Neglected Diseases initiative $982,436 Details
Discovery Drug Lead Identification NTD (Chagas disease) Drug 2016 COMPLETE Identification of lead compounds for Leishmania donovani and/or Trypanosoma cruzi Daiichi Sankyo, Inc.,Drugs for Neglected Diseases initiative $780,000 Details
Discovery Drug Lead Identification NTD (Chagas disease / Leishmaniasis) Drug 2016 COMPLETE Neglected Tropical Diseases Drug Discovery Booster II Eisai Co., Ltd.,SHIONOGI & CO., LTD.,Takeda Pharmaceutical Company Limited,Drugs for Neglected Diseases initiative $549,447 Details
Discovery Drug Lead Identification NTD (Chagas disease / Leishmaniasis) Drug 2017 ACTIVE Neglected Tropical Diseases Drug Discovery Booster III Astellas Pharma Inc.,Eisai Co., Ltd.,SHIONOGI & CO., LTD.,Takeda Pharmaceutical Company Limited,Drugs for Neglected Diseases initiative $1,498,328 Details
Discovery Drug Target Validation NTD (Chagas disease) Drug 2017 ACTIVE Target determination and exploratory research for discovery of new drugs against Chagas disease. High Energy Accelerator Research Organization (KEK),London School of Hygiene and Tropical Medicine(LSHTM),National Institute of Advanced Industrial Science and Technology,Institute of Tropical Medicine (NEKKEN) Nagasaki University $882,350 Details
Discovery Drug Hit Identification NTD (Chagas disease / Leishmaniasis) Drug 2017 ACTIVE Chagas disease and Leishmaniasis Screening between DNDi and Daiichi Sankyo Novare Daiichi Sankyo RD Novare Co., Ltd.,Drugs for Neglected Diseases initiative $119,000 Details
Discovery Drug Hit Identification NTD (Chagas disease / Leishmaniasis) Drug 2019 ACTIVE Screening project between Mitsubishi Tanabe and DNDi Mitsubishi Tanabe Pharma,Drugs for Neglected Diseases initiative $150,000 Details
Discovery Diagnostic Development Feasibility NTD (Schistosomiasis) Diagnostic 2014 COMPLETE Development of a sensitive and specific point-of-care diagnostics for Asian zoonotic schistosomiasis Graduate School of Agricultural and Life Sciences, The University of Tokyo,InBios International, Inc.,University of the Philippines,National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine $779,036 Details
Discovery Diagnostic Concept Development NTD (Schistosomiasis) Diagnostic 2017 ACTIVE Novel diagnostics for schistosomiasis control: development of defined antigens for detection of Schistosoma infection-specific antibodies in blood and urine Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Leiden University Medical Center,Lygature $763,890 Details
Discovery Diagnostic Concept Development NTD (Mycetoma) Diagnostic 2019 ACTIVE MycEXomics aims to develop a field-friendly point-of-care diagnostic test for mycetoma RIKEN,Hospital General de Mexico,Mycetoma Research Centre (MRC), University of Khartoum,Erasmus University Medical Center $285,937 Details
Preclinical Drug Preclinical development Malaria Drug 2013 TERMINATED Development of ELQ300 as a long acting antimalarial Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV) $560,000 Details
Preclinical Drug Preclinical development Malaria Drug 2014 COMPLETE Preclinical and clinical development of (+)-SJ000557733, a novel inhibitor of Plasmodium ATP4 Eisai Co., Ltd.,Medicines for Malaria Venture (MMV),St. Jude Children’s Research Hospital $3,768,922 Details
Preclinical Drug Lead Optimization Malaria Drug 2014 COMPLETE Lead optimization of a novel mechanism-of-action antimalarial Eisai Co., Ltd.,Broad Institute $2,997,525 Details
Preclinical Drug Lead Optimization Malaria Drug 2015 COMPLETE E209 a tetraoxane based rapidly acting antimalarial – candidate selection Eisai Co., Ltd.,University of Liverpool,Liverpool School of Tropical Medicine $207,753 Details
Preclinical Drug Lead Optimization Malaria Drug 2016 ACTIVE Development of a novel mechanism-of-action antimalarial drug with multistage activity Eisai Co., Ltd.,Medicines for Malaria Venture (MMV),Broad Institute $1,999,993 Details
Preclinical Drug Preclinical development Malaria Drug 2016 TERMINATED DSM421 Clinical Development up to phase IIa GO Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV) $7,499,822 Details
Preclinical Drug Lead Optimization Malaria Drug 2016 TERMINATED Identification of pre-clinical candidate as an anti-malarial agent Daiichi Sankyo, Inc.,Medicines for Malaria Venture (MMV) $1,761,309 Details
Preclinical Drug Lead Optimization Malaria Drug 2017 COMPLETE Lead optimization of potent Gwt1p inhibitors toward a new antimalarial drug with a novel mechanism of action Eisai Co., Ltd.,Medicines for Malaria Venture (MMV) $2,639,670 Details
Preclinical Drug Preclinical development Malaria Drug 2018 ACTIVE Preclinical development of a novel mechanism-of-action antimalarial drug with multistage activity Eisai Co., Ltd.,Broad Institute $5,368,224 Details
Preclinical Drug Lead Optimization Malaria Drug 2018 ACTIVE Preclinical development of a new class of Plasmodium DHODH inhibitor for the treatment of malaria Eisai Co., Ltd.,Medicines for Malaria Venture (MMV),Broad Institute $4,214,187 Details
Preclinical Drug Lead Optimization Malaria Drug 2018 ACTIVE Mitsubishi Tanabe Lead Optimization of Anti-Malarials Mitsubishi Tanabe Pharma,Medicines for Malaria Venture (MMV) $1,922,475 Details
Preclinical Drug Preclinical development Malaria Drug 2019 ACTIVE Preclinical studies of potent Gwt1p inhibitor toward IND for antimalarial agent with novel mechanism of action Eisai Co., Ltd.,Medicines for Malaria Venture (MMV) $6,828,394 Details
Preclinical Drug Preclinical development Malaria Drug 2019 ACTIVE Preclinical and Clinical Development of SJ733, a Novel PfATP4 Inhibitor for the Treatment of Severe Malaria Eisai Co., Ltd.,University of Kentucky $5,590,091 Details
Preclinical Vaccine Lead Optimization Malaria Vaccine 2015 COMPLETE Lead optimization of an evolution-proof malaria transmission-blocking vaccine immunogen that is based on a mosquito protein target and effective against both P.falciparum and P. vivax CellFree Sciences Co. Ltd.,Infectious Disease Research Institute,The University of Florida $419,285 Details
Preclinical Vaccine Preclinical Development Malaria Vaccine 2017 ACTIVE Title: Process Development and Clinical Manufacturing of an Immuno-focused, Mosquito-based Pan-malaria transmission-blocking vaccine: AnAPN1 v. 2.0 CellFree Sciences Co. Ltd.,Centre Pasteur du Cameroun (CPC),Hamamatsu Pharma Research,Infectious Disease Research Institute,Ology Bioservices Inc.,The University of Florida $3,484,217 Details
Preclinical Vaccine Preclinical Development Malaria Vaccine 2019 ACTIVE Preclinical development of malaria transmission-blocking vaccine candidate Pfs230D1+ formulated with SA-1 adjuvant Ehime University,Sumitomo Dainippon Pharma Co., Ltd.,PATH $5,007,283 Details
Preclinical Diagnostic Product Design Malaria Diagnostic 2019 ACTIVE Commercial Development of a Saliva-based Malaria Asymptomatic and Asexual Rapid Test (SMAART-1) CellFree Sciences Co. Ltd.,ERADA Technology Alliance, Ltd.,Frontier Institute Co., Ltd.,Oasis Diagnostics Corp.,The University of Florida $1,382,696 Details
Preclinical Drug Lead Optimization Tuberculosis Drug 2017 ACTIVE Lead optimization of novel azetidine-based tryptophan synthase inhibitors as new mechanism of action treatment of tuberculosis Eisai Co., Ltd.,Colorado State University,The Global Alliance for TB Drug Development,The University of Chicago,Broad Institute $2,003,324 Details
Preclinical Vaccine Lead Optimization Tuberculosis Vaccine 2013 TERMINATED Development of rhPIV2 as a Potential New TB Vaccine Candidate National Institutes of Biomedical Innovation, Health and Nutrition,Aeras $5,649,620 Details
Preclinical Vaccine Lead Optimization Tuberculosis Vaccine 2013 TERMINATED Development of recombinant hPIV2 virus vector as a new TB vaccine National Institutes of Biomedical Innovation, Health and Nutrition,Aeras $700,000 Details
Preclinical Drug Lead Optimization NTD (Lymphatic filariasis / Onchocerciasis) Drug 2013 COMPLETE Anti-Wolbachia targeted macrofilaricidal drug discovery-lead optimization of lead series chemotypes to deliver novel pre-clinical candidates Eisai Co., Ltd.,University of Liverpool,Liverpool School of Tropical Medicine $1,093,166 Details
Preclinical Drug Lead Optimization NTD (Leishmaniasis) Drug 2014 COMPLETE Lead optimization of the aminopyrazole series for visceral leishmaniasis Takeda Pharmaceutical Company Limited,Drugs for Neglected Diseases initiative $4,022,552 Details
Preclinical Drug Lead Optimization NTD (Soil-transmitted helminthiasis) Drug 2015 COMPLETE Cry5B consortium for soil-transmitted helminths Meiji Seika Pharma Co., Ltd.,University of Massachusetts Medical School,PATH $1,002,996 Details
Preclinical Drug Preclinical development NTD (Leishmaniasis) Drug 2015 COMPLETE Preclinical efficacy of CpG D35 combination therapy for treatment of complicated cutaneous leishmaniasis GeneDesign, Inc,Drugs for Neglected Diseases initiative $687,715 Details
Preclinical Drug Preclinical development NTD (Leishmaniasis) Drug 2016 ACTIVE Preclinical development of CpG D35 for combined treatment of cutaneous leishmaniasis GeneDesign, Inc,Drugs for Neglected Diseases initiative $4,918,672 Details
Preclinical Drug Preclinical development NTD (Dengue) Drug 2016 COMPLETE Preclinical development of an anti-Dengue virus antibody that neutralizes all four serotypes Chugai Pharmaceutical Co., Ltd.,A∗STAR′s Singapore Immunology Network (SIgN) $5,348,894 Details
Preclinical Drug Preclinical development NTD (Leishmaniasis) Drug 2017 ACTIVE Preclinical development and phase I activities on a selected aminopyrazole compound for visceral leishmaniasis Takeda Pharmaceutical Company Limited,Drugs for Neglected Diseases initiative $6,047,757 Details
Preclinical Drug Preclinical development NTD (Dengue) Drug 2018 ACTIVE Preclinical development of an anti-Dengue virus antibody that neutralizes all four serotypes Chugai Pharmaceutical Co., Ltd.,A∗STAR′s Singapore Immunology Network (SIgN) $4,892,737 Details
Preclinical Drug Preclinical development NTD (Lymphatic filariasis / Onchocerciasis) Drug 2019 ACTIVE Development of AWZ1066S, A Small Molecule anti-Wolbachia Candidate Macrofilaricide Drug Eisai Co., Ltd.,University of Liverpool,Liverpool School of Tropical Medicine $4,335,812 Details
Preclinical Drug Lead Optimization NTD (Chagas disease) Drug 2019 ACTIVE Lead optimization of a candidate series active against Chagas Disease Daiichi Sankyo, Inc.,Drugs for Neglected Diseases initiative $4,318,565 Details
Preclinical Vaccine Preclinical Development NTD (Dengue) Vaccine 2014 COMPLETE Development of a Live Attenuated Tetravalent Dengue Vaccine The Chemo-Sero-Therapeutic Research Institute (KAKETSUKEN),Mahidol University $3,450,276 Details
Preclinical Vaccine Preclinical Development NTD (Chagas disease) Vaccine 2014 COMPLETE Adjuvant Technologies to Advance Chagas Disease Vaccine Development Eisai Co., Ltd.,Baylor College of Medicine (BCM),Aeras,Sabin Vaccine Institute $2,000,000 Details
Preclinical Vaccine Lead Optimization NTD (Leishmaniasis) Vaccine 2015 COMPLETE Live attenuated prophylactic vaccine for leishmaniasis Institute of Tropical Medicine (NEKKEN) Nagasaki University ,McGill University ,The Ohio State University $1,832,967 Details
Preclinical Vaccine Preclinical Development NTD (Dengue) Vaccine 2015 COMPLETE Preclinical development of MVDVax, a new dengue vaccine Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Institut Pasteur,European Vaccine Initiative (EVI) $612,902 Details
Preclinical Vaccine Preclinical Development NTD (Leishmaniasis) Vaccine 2016 ACTIVE Preclinical and preparation of early clinical testing of a new vaccine candidate against cutaneous leishmaniasis Nagasaki University,London School of Hygiene and Tropical Medicine(LSHTM),Mologen ,Charité –Universitätsmedizin Berlin,European Vaccine Initiative (EVI) $4,096,664 Details
Preclinical Vaccine Preclinical Development NTD (Dengue) Vaccine 2016 COMPLETE Development of novel dengue virus-like particle (VLP) vaccines against all four serotypes Institute of Tropical Medicine (NEKKEN) Nagasaki University ,National Institute of Infectious Diseases,VLP Therapeutics $986,540 Details
Preclinical Vaccine Preclinical Development NTD (Dengue) Vaccine 2018 ACTIVE The development and production of cGMP lots of a novel tetravalent dengue virus-like particle (VLP) vaccine Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Johns Hopkins University,Latham BioPharm Group,National Institute of Infectious Diseases,VLP Therapeutics $4,422,091 Details
Preclinical Vaccine Preclinical Development NTD (Leishmaniasis) Vaccine 2018 ACTIVE Live attenuated prophylactic vaccine for leishmaniasis Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Gennova Biopharmaceuticals Ltd.,McGill University ,The Ohio State University $3,998,989 Details
Preclinical Vaccine Preclinical Development NTD (Leishmaniasis) Vaccine 2018 ACTIVE Immune therapy to prevent VL complications University of Tokyo,International Center for Diarrheal Disease Research Bangladesh,Infectious Disease Research Institute $558,315 Details
Preclinical Vaccine Lead Optimization NTD (Chagas disease) Vaccine 2019 ACTIVE Optimization and pre-clinical development of a Trypanosoma cruzi Cyp19 knock-out strain as a live vaccine for Chagas disease. Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Ohio University,The Ohio State University $1,097,927 Details
Preclinical Diagnostic Product Design NTD (Leishmaniasis) Diagnostic 2019 ACTIVE Production, validation and use of Leishmanin skin test (LST) for detection of Leishmania exposure and immunity Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Gennova Biopharmaceuticals Ltd.,McGill University ,U.S. Food and Drug Administration,The Ohio State University $2,257,699 Details
Clinical Drug Clinical Phase2 Malaria Drug 2013 COMPLETE Development of DSM265 as a long acting antimalarial compound Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV) $2,538,796 Details
Clinical Drug Clinical Phase1 Malaria Drug 2014 COMPLETE Testing DSM265, a novel antimalarial acting through DHODH, in combination with OZ439 Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV) $1,290,883 Details
Clinical Drug Clinical Phase2 Malaria Drug 2015 COMPLETE Commercial formulation development of DSM265 Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV) $1,905,341 Details
Clinical Drug Clinical Phase2 Malaria Drug 2016 ACTIVE Phase 2 Trial of SJ733, a Novel PfATP4 Inhibitor for Malaria Eisai Co., Ltd.,Medicines for Malaria Venture (MMV),University of Kentucky $4,500,001 Details
Clinical Drug Clinical Phase2 Malaria Drug 2016 COMPLETE Formulation Optimization Work on DSM265 Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV) $1,589,999 Details
Clinical Vaccine Phase1 Clinical Development Malaria Vaccine 2013 COMPLETE Clinical Development of BK-SE36/CpG Malaria Vaccine Research Institute for Microbial Diseases (RIMD), Osaka University,Gulu University, Uganda $714,500 Details
Clinical Vaccine Phase1 Clinical Development Malaria Vaccine 2014 COMPLETE Clinical development of the BK-SE36 malaria vaccine candidate Research Institute for Microbial Diseases (RIMD), Osaka University,Centre National de Recherche et de Formation sur le Paludisme (CNRFP),European Vaccine Initiative (EVI) $999,999 Details
Clinical Vaccine Phase1 Clinical Development Malaria Vaccine 2016 ACTIVE Clinical Development of BK-SE36/CpG Malaria Vaccine: safety evaluation of BK-SE36/CpG in the malaria endemic population Medical Center for Translational Research (MTR), Osaka University Hospital,Institut de Recherche en Sciences de la Santé (IRSS),Nobelpharma Co., Ltd.,Research Institute for Microbial Diseases (RIMD), Osaka University,European Vaccine Initiative (EVI) $2,781,588 Details
Clinical Vaccine Phase1 Clinical Development Malaria Vaccine 2019 ACTIVE Preparatory phase II for the malaria vaccine candidate NPC-SE36/CpG Nobelpharma Co., Ltd.,Groupe de Recherche Action en Santé (GRAS),Research Institute for Microbial Diseases (RIMD), Osaka University,European Vaccine Initiative (EVI) $1,870,777 Details
Clinical Diagnostic Product Validation Malaria Diagnostic 2015 COMPLETE Development of a fully automated malaria diagnostic system and field evaluation for practical use Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Juntendo University,Kenya Medical Research Institute (KEMRI-CGHR),Malaria No More Japan (MNMJ),National Institute of Advanced Industrial Science and Technology,Panasonic Corporation $964,500 Details
Clinical Vaccine Phase2 Clinical Development Tuberculosis Vaccine 2015 ACTIVE DAR-901 whole cell booster vaccine to prevent TB infection in adolescents (“DAR-PIA”) Tokyo Medical and Dental University,Muhimbili University of Health and Allied Sciences (MUHAS),Geisel School of Medicine at Dartmouth $1,423,590 Details
Clinical Diagnostic Product Validation Tuberculosis Diagnostic 2015 COMPLETE Highly Sensitive POC TB-LAM Rapid Diagnostic Test Fujifilm Corporation ,Foundation for Innovative New Diagnostics (FIND) $2,160,577 Details
Clinical Diagnostic Product Validation Tuberculosis Diagnostic 2017 ACTIVE Fujifilm SILVAMP TB LAM – A Sensitive point-of-care Tuberculosis Test Fujifilm Corporation ,Foundation for Innovative New Diagnostics (FIND) $4,217,169 Details
Clinical Drug Clinical Phase2 NTD (Chagas disease) Drug 2013 COMPLETE A new treatment for Chagas disease Eisai Co., Ltd.,Drugs for Neglected Diseases initiative $3,840,892 Details
Clinical Drug Clinical Phase1 NTD (Schistosomiasis) Drug 2013 COMPLETE Development and registration of a new praziquantel pediatric formulation for the treatment of schistosomiasis Astellas Pharma Inc.,Farmanguinhos,Merck KGaA,Simcyp Limited,Swiss Tropical and Public Health Institute,Lygature $1,864,898 Details
Clinical Drug Clinical Phase2 NTD (Schistosomiasis) Drug 2014 COMPLETE Development and registration of a new praziquantel pediatric formulation for the treatment of schistosomiasis Astellas Pharma Inc.,Farmanguinhos,Merck KGaA,Simcyp Limited,Swiss Tropical and Public Health Institute,Lygature $4,856,513 Details
Clinical Drug Clinical Phase3 NTD (Schistosomiasis) Drug 2016 ACTIVE Development and registration of a new pediatric praziquantel formulation for the treatment of schistosomiasis in preschool-aged children Astellas Pharma Inc.,Farmanguinhos,Merck KGaA,Schistosomiasis Control Initiative (SCI),Simcyp Limited,Swiss Tropical and Public Health Institute,Lygature $4,679,698 Details
Clinical Drug Clinical Phase2 NTD (Mycetoma) Drug 2017 ACTIVE Mycetoma Treatment, Fosravuconazole Clinical Trial Eisai Co., Ltd.,Drugs for Neglected Diseases initiative $2,526,217 Details
Clinical Drug Registration NTD (Schistosomiasis) Drug 2018 ACTIVE Treating schistosomiasis in preschool-aged children: development, registration and access to L-praziquantel orally disintegrating tablet formulation Astellas Pharma Inc.,Farmanguinhos,Kenya Medical Research Institute (KEMRI-CGHR),Merck KGaA,Schistosomiasis Control Initiative (SCI),Swiss Tropical and Public Health Institute,Université Félix Houphouët Boigny (UFHB),Lygature $4,523,295 Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2013
  • Status: 
  • Project: Screening Program
  • Partner: Eisai Co., Ltd.,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $104,264
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2013
  • Status: 
  • Project: Screening Program
  • Partner: Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $73,940
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2013
  • Status: 
  • Project: Screening Program
  • Partner: Kitasato Institute,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $570
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2013
  • Status: 
  • Project: Screening Program
  • Partner: Daiichi Sankyo, Inc.,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $241,372
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2013
  • Status: 
  • Project: Screening Program
  • Partner: Institute of Microbial Chemistry,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $11,286
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2014
  • Status: 
  • Project: Screening Program
  • Partner: Mitsubishi Tanabe Pharma,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $186,420
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2014
  • Status: 
  • Project: Screening Program
  • Partner: Sumitomo Dainippon Pharma Co., Ltd.,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $137,883
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2014
  • Status: 
  • Project: Design and Cost-effective de novo Synthesis of Aza-artemisinins
  • Partner: Kitasato Institute,Medicines for Malaria Venture (MMV),Hokkaido University
  • Awarded Amount: $60,000
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2014
  • Status: 
  • Project: Identification of lead compounds for anti-Malarial agent
  • Partner: Daiichi Sankyo, Inc.,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $636,941
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2015
  • Status: 
  • Project: Screening Program
  • Partner: Daiichi Sankyo RD Novare Co., Ltd.,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $150,000
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2015
  • Status: 
  • Project: Hit-to-Lead Discovery for New Anti-malarials in Collaboration between MMV and Eisai
  • Partner: Eisai Co., Ltd.,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $779,760
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2015
  • Status: 
  • Project: Antimalarial hits from whole cell screening
  • Partner: Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $764,033
Details
  • Development Stage: Discovery
  • Current Stage: Drug Target Validation
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2015
  • Status: 
  • Project: Proteasome inhibitors as new potent resistance-­reversing antimalarials
  • Partner: Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV),The University of Melbourne
  • Awarded Amount: $297,133
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2015
  • Status: 
  • Project: Screening Program
  • Partner: Op Bio Factory Co., Ltd.,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $68,400
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2016
  • Status: 
  • Project: New Hit-to-Lead Activity for New Anti-Malarias between MMV and Eisai
  • Partner: Eisai Co., Ltd.,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $750,000
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2016
  • Status: 
  • Project: Mitsubishi Tanabe malaria Hit-to-Lead
  • Partner: Mitsubishi Tanabe Pharma,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $618,222
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2016
  • Status: 
  • Project: New Hit-to-Lead Activity for New Anti-Malarias between MMV and Takeda
  • Partner: Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $483,360
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2017
  • Status: 
  • Project: Screening Program
  • Partner: Astellas Pharma Inc.,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $65,836
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2017
  • Status: 
  • Project: HTL for selective Plasmodium proteasome inhibitors as new potent resistance-reversing antimalarials
  • Partner: Takeda Pharmaceutical Company Limited,The University of Melbourne’s Bio21 Molecular Science and Biotechnology Institute,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $461,245
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2017
  • Status: 
  • Project: New Hit-to-Lead Activity for New Anti-Malaria drugs between MMV and Sumitomo Dainippon Pharma
  • Partner: Sumitomo Dainippon Pharma Co., Ltd.,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $445,500
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2017
  • Status: 
  • Project: Screening Program
  • Partner: Eisai Co., Ltd.,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $49,500
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2018
  • Status: 
  • Project: New Hit-to-Lead Activity for New Anti-Malarials between MMV and Takeda
  • Partner: Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $528,000
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2018
  • Status: 
  • Project: Screening Program
  • Partner: University of Tokyo,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $150,000
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2019
  • Status: 
  • Project: Development of nucleoside sulfamates as novel antimalarials
  • Partner: Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV),The University of Melbourne’s Bio21 Molecular Science and Biotechnology Institute
  • Awarded Amount: $1,016,129
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2019
  • Status: 
  • Project: Proteasome inhibitors as new potent antimalarials
  • Partner: Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV),The University of Melbourne’s Bio21 Molecular Science and Biotechnology Institute
  • Awarded Amount: $526,140
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2019
  • Status: 
  • Project: Screening project between Takeda and MMV
  • Partner: Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $41,962
Details
  • Development Stage: Discovery
  • Current Stage: Vaccine Technology Platform Identification
  • Disease: Malaria
  • Intervention: Vaccine
  • RFP Year: 2013
  • Status: 
  • Project: Accelerating Development of Vaccines for Malaria Elimination Using a Novel Clinical Target Validation Approach
  • Partner: CellFree Sciences Co. Ltd.,Ehime University,PATH Malaria Vaccine Initiative
  • Awarded Amount: $591,396
Details
  • Development Stage: Discovery
  • Current Stage: Vaccine Technology Platform Identification
  • Disease: Malaria
  • Intervention: Vaccine
  • RFP Year: 2014
  • Status: 
  • Project: Accelerating Development of Transmission-Blocking Vaccines for Malaria Elimination Using a Novel Vaccine Candidate
  • Partner: Ehime University,PATH Malaria Vaccine Initiative
  • Awarded Amount: $766,098
Details
  • Development Stage: Discovery
  • Current Stage: Vaccine Antigen Identification
  • Disease: Malaria
  • Intervention: Vaccine
  • RFP Year: 2016
  • Status: 
  • Project: A Vaccine to Block Malaria Transmission: Pfs230 Antigen Design and Display
  • Partner: Ehime University,PATH Malaria Vaccine Initiative
  • Awarded Amount: $595,650
Details
  • Development Stage: Discovery
  • Current Stage: Vaccine Antigen Identification
  • Disease: Malaria
  • Intervention: Vaccine
  • RFP Year: 2017
  • Status: 
  • Project: Identification of Vaccine Targets that Will Block the Interaction of Plasmodium falciparum Malaria Parasites with a Complement Regulator
  • Partner: Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Antigen Discovery, Inc.,The Pennsylvania State University
  • Awarded Amount: $881,900
Details
  • Development Stage: Discovery
  • Current Stage: Vaccine Antigen Identification
  • Disease: Malaria
  • Intervention: Vaccine
  • RFP Year: 2018
  • Status: 
  • Project: Further development of a new asexual blood-stage malaria vaccine candidate
  • Partner: Ehime University,iBET,European Vaccine Initiative (EVI)
  • Awarded Amount: $930,571
Details
  • Development Stage: Discovery
  • Current Stage: Vaccine Antigen Identification
  • Disease: Malaria
  • Intervention: Vaccine
  • RFP Year: 2019
  • Status: 
  • Project: Co-delivery of Pfs230C1 and CSP with CoPoP, a versatile, potent liposomal adjuvant system for multistage malaria vaccine
  • Partner: Ehime University,University at Buffalo, The State University of New York,PATH Malaria Vaccine Initiative
  • Awarded Amount: $972,951
Details
  • Development Stage: Discovery
  • Current Stage: Vaccine Technology Platform Identification
  • Disease: Malaria
  • Intervention: Vaccine
  • RFP Year: 2019
  • Status: 
  • Project: Development of a novel Pvs25 nucleoside-modified mRNA vaccine that induces potent and long-lasting transmission blocking immunity
  • Partner: Ehime University,University of Pennsylvania,Mahidol University
  • Awarded Amount: $960,771
Details
  • Development Stage: Discovery
  • Current Stage: Vaccine Vaccine Concept Development
  • Disease: Malaria
  • Intervention: Vaccine
  • RFP Year: 2019
  • Status: 
  • Project: Made-in-Japan next-generation vaccine platform effective for multistage Plasmodium for infants
  • Partner: Hokkaido University,Jichi Medical University,Toyama University,University of Cambridge,Kanazawa University
  • Awarded Amount: $526,900
Details
  • Development Stage: Discovery
  • Current Stage: Diagnostic Technical Feasibility
  • Disease: Malaria
  • Intervention: Diagnostic
  • RFP Year: 2015
  • Status: 
  • Project: Development of serological biomarkers as indicators of recent and asymptomatic infections for innovative tools to accelerate malaria elimination
  • Partner: CellFree Sciences Co. Ltd.,Foundation for Innovative New Diagnostics (FIND),Proteo-Science Centre, Ehime University,The Walter and Eliza Hall Institute of Medical Research
  • Awarded Amount: $993,030
Details
  • Development Stage: Discovery
  • Current Stage: Diagnostic Concept Development
  • Disease: Malaria
  • Intervention: Diagnostic
  • RFP Year: 2017
  • Status: 
  • Project: Towards rapid diagnosis of Plasmodium vivax malaria hypnozoite infection
  • Partner: National Institute of Technology, Kumamoto College,Biomedical Primate Research Centre,Institute of Tropical Medicine (NEKKEN) Nagasaki University
  • Awarded Amount: $728,830
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2013
  • Status: 
  • Project: Screening Program
  • Partner: SHIONOGI & CO., LTD.,The Global Alliance for TB Drug Development
  • Awarded Amount: $105,450
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2013
  • Status: 
  • Project: Screening Program
  • Partner: Takeda Pharmaceutical Company Limited,The Global Alliance for TB Drug Development
  • Awarded Amount: $55,550
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2013
  • Status: 
  • Project: Screening Program
  • Partner: Daiichi Sankyo, Inc.,The Global Alliance for TB Drug Development
  • Awarded Amount: $135,300
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2014
  • Status: 
  • Project: Screening Program
  • Partner: Daiichi Sankyo RD Novare Co., Ltd.,The Global Alliance for TB Drug Development
  • Awarded Amount: $150,000
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2014
  • Status: 
  • Project: Screening Program
  • Partner: Op Bio Factory Co., Ltd.,The Global Alliance for TB Drug Development
  • Awarded Amount: $150,000
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2015
  • Status: 
  • Project: Hit-to-Lead Development of anti-TB Phenotypic Screening Hits
  • Partner: The Research Institute of Tuberculosis, Japan Anti-tuberculosis Association,The Global Alliance for TB Drug Development,SHIONOGI & CO., LTD.
  • Awarded Amount: $999,720
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2015
  • Status: 
  • Project: Development of Phenotypic Screening Hits against Mycobacterium tuberculosis
  • Partner: Takeda Pharmaceutical Company Limited,The Global Alliance for TB Drug Development
  • Awarded Amount: $792,165
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2015
  • Status: 
  • Project: Screening Program
  • Partner: Chugai Pharmaceutical Co., Ltd.,The Global Alliance for TB Drug Development
  • Awarded Amount: $150,000
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2015
  • Status: 
  • Project: Screening Program
  • Partner: Toyama Prefectural University,The Global Alliance for TB Drug Development,HYPHAGENESIS INC.
  • Awarded Amount: $150,000
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2015
  • Status: 
  • Project: Screening Program
  • Partner: Mitsubishi Tanabe Pharma,The Global Alliance for TB Drug Development
  • Awarded Amount: $132,000
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2015
  • Status: 
  • Project: Screening Program
  • Partner: Sumitomo Dainippon Pharma Co., Ltd.,The Global Alliance for TB Drug Development
  • Awarded Amount: $79,200
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2015
  • Status: 
  • Project: Identification of lead compounds as novel anti‐TB agents
  • Partner: Daiichi Sankyo, Inc.,The Global Alliance for TB Drug Development
  • Awarded Amount: $908,231
Details
  • Development Stage: Discovery
  • Current Stage: Drug Target Validation
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2016
  • Status: 
  • Project: Host-directed drug targeting against tuberculosis
  • Partner: RIKEN,International Centre for Genetic Engineering and Biotechnology
  • Awarded Amount: $204,990
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2017
  • Status: 
  • Project: Screening Program
  • Partner: Astellas Pharma Inc.,The Global Alliance for TB Drug Development
  • Awarded Amount: $99,986
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2018
  • Status: 
  • Project: Hit-to-Lead Development of Novel anti-TB Natural Products
  • Partner: Daiichi Sankyo RD Novare Co., Ltd.,The Global Alliance for TB Drug Development
  • Awarded Amount: $1,192,440
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2018
  • Status: 
  • Project: Screening Program
  • Partner: Fujifilm Corporation ,The Global Alliance for TB Drug Development
  • Awarded Amount: $110,000
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2019
  • Status: 
  • Project: Hit-to-Lead Development of Phenotypic and Mechanism-based Screen Hits
  • Partner: Takeda Pharmaceutical Company Limited,The Global Alliance for TB Drug Development
  • Awarded Amount: $1,112,058
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2019
  • Status: 
  • Project: Hit-to-Lead Development of Phenotypic Screening Hits
  • Partner: Chugai Pharmaceutical Co., Ltd.,The Global Alliance for TB Drug Development
  • Awarded Amount: $953,159
Details
  • Development Stage: Discovery
  • Current Stage: Vaccine Vaccine Concept Development
  • Disease: Tuberculosis
  • Intervention: Vaccine
  • RFP Year: 2016
  • Status: 
  • Project: Development of a new mucosal vaccine for Tuberculosis using antibody engineering
  • Partner: University of Tokyo,Universidad de Concepcion,Instituto de Nutricion “Salvador Zubiran”,Universiti Sains Malaysia
  • Awarded Amount: $373,561
Details
  • Development Stage: Discovery
  • Current Stage: Diagnostic Concept Development
  • Disease: Tuberculosis
  • Intervention: Diagnostic
  • RFP Year: 2018
  • Status: 
  • Project: Development of LFA platform for improving sensitivity of Point-of-Care assays for infectious disease with main focus on Tuberculosis and Malaria.
  • Partner: Asahi Kasei Corporation,Biopromic AB
  • Awarded Amount: $1,000,000
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: NTD (Chagas disease)
  • Intervention: Drug
  • RFP Year: 2013
  • Status: 
  • Project: Optimization of Diversity-Oriented Synthesis (DOS)-derived trypanocidal small molecule ML341 towards investigational new drug status for Chagas disease
  • Partner: Eisai Co., Ltd.,Broad Institute
  • Awarded Amount: $500,000
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: NTD (Chagas disease / Leishmaniasis)
  • Intervention: Drug
  • RFP Year: 2013
  • Status: 
  • Project: Screening Program
  • Partner: Eisai Co., Ltd.,Drugs for Neglected Diseases initiative
  • Awarded Amount: $75,582
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: NTD (Chagas disease / Leishmaniasis)
  • Intervention: Drug
  • RFP Year: 2013
  • Status: 
  • Project: Screening Program
  • Partner: Takeda Pharmaceutical Company Limited,Drugs for Neglected Diseases initiative
  • Awarded Amount: $75,582
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: NTD (Chagas disease / Leishmaniasis)
  • Intervention: Drug
  • RFP Year: 2013
  • Status: 
  • Project: Screening Program
  • Partner: Kitasato Institute,Drugs for Neglected Diseases initiative
  • Awarded Amount: $0
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: NTD (Chagas disease / Leishmaniasis)
  • Intervention: Drug
  • RFP Year: 2013
  • Status: 
  • Project: Screening Program
  • Partner: Institute of Microbial Chemistry,Drugs for Neglected Diseases initiative
  • Awarded Amount: $7,558
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: NTD (Chagas disease / Leishmaniasis)
  • Intervention: Drug
  • RFP Year: 2014
  • Status: 
  • Project: Neglected Tropical Diseases Drug Discovery Booster
  • Partner: Eisai Co., Ltd.,SHIONOGI & CO., LTD.,Takeda Pharmaceutical Company Limited,Drugs for Neglected Diseases initiative
  • Awarded Amount: $795,437
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: NTD (Leishmaniasis)
  • Intervention: Drug
  • RFP Year: 2015
  • Status: 
  • Project: Screening Program
  • Partner: Eisai Co., Ltd.,Drugs for Neglected Diseases initiative
  • Awarded Amount: $31,000
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: NTD (Chagas disease)
  • Intervention: Drug
  • RFP Year: 2015
  • Status: 
  • Project: Screening Program
  • Partner: Daiichi Sankyo, Inc.,Drugs for Neglected Diseases initiative
  • Awarded Amount: $210,050
Details
  • Development Stage: Discovery
  • Current Stage: Drug Target Validation
  • Disease: NTD (Chagas disease / Leishmaniasis)
  • Intervention: Drug
  • RFP Year: 2016
  • Status: 
  • Project: Targeting bromodomains for novel anti-parasitic mechanisms of action for malaria, Chagas disease, leishmaniasis and cryptosporidiosis
  • Partner: RIKEN,McGill University ,Medicines for Malaria Venture (MMV),Structural Genomics Consortium at University of Toronto,The University of Melbourne,Drugs for Neglected Diseases initiative
  • Awarded Amount: $982,436
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: NTD (Chagas disease)
  • Intervention: Drug
  • RFP Year: 2016
  • Status: 
  • Project: Identification of lead compounds for Leishmania donovani and/or Trypanosoma cruzi
  • Partner: Daiichi Sankyo, Inc.,Drugs for Neglected Diseases initiative
  • Awarded Amount: $780,000
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: NTD (Chagas disease / Leishmaniasis)
  • Intervention: Drug
  • RFP Year: 2016
  • Status: 
  • Project: Neglected Tropical Diseases Drug Discovery Booster II
  • Partner: Eisai Co., Ltd.,SHIONOGI & CO., LTD.,Takeda Pharmaceutical Company Limited,Drugs for Neglected Diseases initiative
  • Awarded Amount: $549,447
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: NTD (Chagas disease / Leishmaniasis)
  • Intervention: Drug
  • RFP Year: 2017
  • Status: 
  • Project: Neglected Tropical Diseases Drug Discovery Booster III
  • Partner: Astellas Pharma Inc.,Eisai Co., Ltd.,SHIONOGI & CO., LTD.,Takeda Pharmaceutical Company Limited,Drugs for Neglected Diseases initiative
  • Awarded Amount: $1,498,328
Details
  • Development Stage: Discovery
  • Current Stage: Drug Target Validation
  • Disease: NTD (Chagas disease)
  • Intervention: Drug
  • RFP Year: 2017
  • Status: 
  • Project: Target determination and exploratory research for discovery of new drugs against Chagas disease.
  • Partner: High Energy Accelerator Research Organization (KEK),London School of Hygiene and Tropical Medicine(LSHTM),National Institute of Advanced Industrial Science and Technology,Institute of Tropical Medicine (NEKKEN) Nagasaki University
  • Awarded Amount: $882,350
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: NTD (Chagas disease / Leishmaniasis)
  • Intervention: Drug
  • RFP Year: 2017
  • Status: 
  • Project: Chagas disease and Leishmaniasis Screening between DNDi and Daiichi Sankyo Novare
  • Partner: Daiichi Sankyo RD Novare Co., Ltd.,Drugs for Neglected Diseases initiative
  • Awarded Amount: $119,000
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: NTD (Chagas disease / Leishmaniasis)
  • Intervention: Drug
  • RFP Year: 2019
  • Status: 
  • Project: Screening project between Mitsubishi Tanabe and DNDi
  • Partner: Mitsubishi Tanabe Pharma,Drugs for Neglected Diseases initiative
  • Awarded Amount: $150,000
Details
  • Development Stage: Discovery
  • Current Stage: Diagnostic Development Feasibility
  • Disease: NTD (Schistosomiasis)
  • Intervention: Diagnostic
  • RFP Year: 2014
  • Status: 
  • Project: Development of a sensitive and specific point-of-care diagnostics for Asian zoonotic schistosomiasis
  • Partner: Graduate School of Agricultural and Life Sciences, The University of Tokyo,InBios International, Inc.,University of the Philippines,National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine
  • Awarded Amount: $779,036
Details
  • Development Stage: Discovery
  • Current Stage: Diagnostic Concept Development
  • Disease: NTD (Schistosomiasis)
  • Intervention: Diagnostic
  • RFP Year: 2017
  • Status: 
  • Project: Novel diagnostics for schistosomiasis control: development of defined antigens for detection of Schistosoma infection-specific antibodies in blood and urine
  • Partner: Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Leiden University Medical Center,Lygature
  • Awarded Amount: $763,890
Details
  • Development Stage: Discovery
  • Current Stage: Diagnostic Concept Development
  • Disease: NTD (Mycetoma)
  • Intervention: Diagnostic
  • RFP Year: 2019
  • Status: 
  • Project: MycEXomics aims to develop a field-friendly point-of-care diagnostic test for mycetoma
  • Partner: RIKEN,Hospital General de Mexico,Mycetoma Research Centre (MRC), University of Khartoum,Erasmus University Medical Center
  • Awarded Amount: $285,937
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Preclinical development
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2013
  • Status: 
  • Project: Development of ELQ300 as a long acting antimalarial
  • Partner: Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $560,000
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Preclinical development
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2014
  • Status: 
  • Project: Preclinical and clinical development of (+)-SJ000557733, a novel inhibitor of Plasmodium ATP4
  • Partner: Eisai Co., Ltd.,Medicines for Malaria Venture (MMV),St. Jude Children’s Research Hospital
  • Awarded Amount: $3,768,922
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Lead Optimization
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2014
  • Status: 
  • Project: Lead optimization of a novel mechanism-of-action antimalarial
  • Partner: Eisai Co., Ltd.,Broad Institute
  • Awarded Amount: $2,997,525
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Lead Optimization
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2015
  • Status: 
  • Project: E209 a tetraoxane based rapidly acting antimalarial – candidate selection
  • Partner: Eisai Co., Ltd.,University of Liverpool,Liverpool School of Tropical Medicine
  • Awarded Amount: $207,753
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Lead Optimization
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2016
  • Status: 
  • Project: Development of a novel mechanism-of-action antimalarial drug with multistage activity
  • Partner: Eisai Co., Ltd.,Medicines for Malaria Venture (MMV),Broad Institute
  • Awarded Amount: $1,999,993
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Preclinical development
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2016
  • Status: 
  • Project: DSM421 Clinical Development up to phase IIa GO
  • Partner: Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $7,499,822
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Lead Optimization
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2016
  • Status: 
  • Project: Identification of pre-clinical candidate as an anti-malarial agent
  • Partner: Daiichi Sankyo, Inc.,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $1,761,309
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Lead Optimization
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2017
  • Status: 
  • Project: Lead optimization of potent Gwt1p inhibitors toward a new antimalarial drug with a novel mechanism of action
  • Partner: Eisai Co., Ltd.,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $2,639,670
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Preclinical development
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2018
  • Status: 
  • Project: Preclinical development of a novel mechanism-of-action antimalarial drug with multistage activity
  • Partner: Eisai Co., Ltd.,Broad Institute
  • Awarded Amount: $5,368,224
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Lead Optimization
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2018
  • Status: 
  • Project: Preclinical development of a new class of Plasmodium DHODH inhibitor for the treatment of malaria
  • Partner: Eisai Co., Ltd.,Medicines for Malaria Venture (MMV),Broad Institute
  • Awarded Amount: $4,214,187
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Lead Optimization
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2018
  • Status: 
  • Project: Mitsubishi Tanabe Lead Optimization of Anti-Malarials
  • Partner: Mitsubishi Tanabe Pharma,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $1,922,475
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Preclinical development
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2019
  • Status: 
  • Project: Preclinical studies of potent Gwt1p inhibitor toward IND for antimalarial agent with novel mechanism of action
  • Partner: Eisai Co., Ltd.,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $6,828,394
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Preclinical development
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2019
  • Status: 
  • Project: Preclinical and Clinical Development of SJ733, a Novel PfATP4 Inhibitor for the Treatment of Severe Malaria
  • Partner: Eisai Co., Ltd.,University of Kentucky
  • Awarded Amount: $5,590,091
Details
  • Development Stage: Preclinical
  • Current Stage: Vaccine Lead Optimization
  • Disease: Malaria
  • Intervention: Vaccine
  • RFP Year: 2015
  • Status: 
  • Project: Lead optimization of an evolution-proof malaria transmission-blocking vaccine immunogen that is based on a mosquito protein target and effective against both P.falciparum and P. vivax
  • Partner: CellFree Sciences Co. Ltd.,Infectious Disease Research Institute,The University of Florida
  • Awarded Amount: $419,285
Details
  • Development Stage: Preclinical
  • Current Stage: Vaccine Preclinical Development
  • Disease: Malaria
  • Intervention: Vaccine
  • RFP Year: 2017
  • Status: 
  • Project: Title: Process Development and Clinical Manufacturing of an Immuno-focused, Mosquito-based Pan-malaria transmission-blocking vaccine: AnAPN1 v. 2.0
  • Partner: CellFree Sciences Co. Ltd.,Centre Pasteur du Cameroun (CPC),Hamamatsu Pharma Research,Infectious Disease Research Institute,Ology Bioservices Inc.,The University of Florida
  • Awarded Amount: $3,484,217
Details
  • Development Stage: Preclinical
  • Current Stage: Vaccine Preclinical Development
  • Disease: Malaria
  • Intervention: Vaccine
  • RFP Year: 2019
  • Status: 
  • Project: Preclinical development of malaria transmission-blocking vaccine candidate Pfs230D1+ formulated with SA-1 adjuvant
  • Partner: Ehime University,Sumitomo Dainippon Pharma Co., Ltd.,PATH
  • Awarded Amount: $5,007,283
Details
  • Development Stage: Preclinical
  • Current Stage: Diagnostic Product Design
  • Disease: Malaria
  • Intervention: Diagnostic
  • RFP Year: 2019
  • Status: 
  • Project: Commercial Development of a Saliva-based Malaria Asymptomatic and Asexual Rapid Test (SMAART-1)
  • Partner: CellFree Sciences Co. Ltd.,ERADA Technology Alliance, Ltd.,Frontier Institute Co., Ltd.,Oasis Diagnostics Corp.,The University of Florida
  • Awarded Amount: $1,382,696
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Lead Optimization
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2017
  • Status: 
  • Project: Lead optimization of novel azetidine-based tryptophan synthase inhibitors as new mechanism of action treatment of tuberculosis
  • Partner: Eisai Co., Ltd.,Colorado State University,The Global Alliance for TB Drug Development,The University of Chicago,Broad Institute
  • Awarded Amount: $2,003,324
Details
  • Development Stage: Preclinical
  • Current Stage: Vaccine Lead Optimization
  • Disease: Tuberculosis
  • Intervention: Vaccine
  • RFP Year: 2013
  • Status: 
  • Project: Development of rhPIV2 as a Potential New TB Vaccine Candidate
  • Partner: National Institutes of Biomedical Innovation, Health and Nutrition,Aeras
  • Awarded Amount: $5,649,620
Details
  • Development Stage: Preclinical
  • Current Stage: Vaccine Lead Optimization
  • Disease: Tuberculosis
  • Intervention: Vaccine
  • RFP Year: 2013
  • Status: 
  • Project: Development of recombinant hPIV2 virus vector as a new TB vaccine
  • Partner: National Institutes of Biomedical Innovation, Health and Nutrition,Aeras
  • Awarded Amount: $700,000
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Lead Optimization
  • Disease: NTD (Lymphatic filariasis / Onchocerciasis)
  • Intervention: Drug
  • RFP Year: 2013
  • Status: 
  • Project: Anti-Wolbachia targeted macrofilaricidal drug discovery-lead optimization of lead series chemotypes to deliver novel pre-clinical candidates
  • Partner: Eisai Co., Ltd.,University of Liverpool,Liverpool School of Tropical Medicine
  • Awarded Amount: $1,093,166
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Lead Optimization
  • Disease: NTD (Leishmaniasis)
  • Intervention: Drug
  • RFP Year: 2014
  • Status: 
  • Project: Lead optimization of the aminopyrazole series for visceral leishmaniasis
  • Partner: Takeda Pharmaceutical Company Limited,Drugs for Neglected Diseases initiative
  • Awarded Amount: $4,022,552
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Lead Optimization
  • Disease: NTD (Soil-transmitted helminthiasis)
  • Intervention: Drug
  • RFP Year: 2015
  • Status: 
  • Project: Cry5B consortium for soil-transmitted helminths
  • Partner: Meiji Seika Pharma Co., Ltd.,University of Massachusetts Medical School,PATH
  • Awarded Amount: $1,002,996
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Preclinical development
  • Disease: NTD (Leishmaniasis)
  • Intervention: Drug
  • RFP Year: 2015
  • Status: 
  • Project: Preclinical efficacy of CpG D35 combination therapy for treatment of complicated cutaneous leishmaniasis
  • Partner: GeneDesign, Inc,Drugs for Neglected Diseases initiative
  • Awarded Amount: $687,715
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Preclinical development
  • Disease: NTD (Leishmaniasis)
  • Intervention: Drug
  • RFP Year: 2016
  • Status: 
  • Project: Preclinical development of CpG D35 for combined treatment of cutaneous leishmaniasis
  • Partner: GeneDesign, Inc,Drugs for Neglected Diseases initiative
  • Awarded Amount: $4,918,672
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Preclinical development
  • Disease: NTD (Dengue)
  • Intervention: Drug
  • RFP Year: 2016
  • Status: 
  • Project: Preclinical development of an anti-Dengue virus antibody that neutralizes all four serotypes
  • Partner: Chugai Pharmaceutical Co., Ltd.,A∗STAR′s Singapore Immunology Network (SIgN)
  • Awarded Amount: $5,348,894
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Preclinical development
  • Disease: NTD (Leishmaniasis)
  • Intervention: Drug
  • RFP Year: 2017
  • Status: 
  • Project: Preclinical development and phase I activities on a selected aminopyrazole compound for visceral leishmaniasis
  • Partner: Takeda Pharmaceutical Company Limited,Drugs for Neglected Diseases initiative
  • Awarded Amount: $6,047,757
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Preclinical development
  • Disease: NTD (Dengue)
  • Intervention: Drug
  • RFP Year: 2018
  • Status: 
  • Project: Preclinical development of an anti-Dengue virus antibody that neutralizes all four serotypes
  • Partner: Chugai Pharmaceutical Co., Ltd.,A∗STAR′s Singapore Immunology Network (SIgN)
  • Awarded Amount: $4,892,737
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Preclinical development
  • Disease: NTD (Lymphatic filariasis / Onchocerciasis)
  • Intervention: Drug
  • RFP Year: 2019
  • Status: 
  • Project: Development of AWZ1066S, A Small Molecule anti-Wolbachia Candidate Macrofilaricide Drug
  • Partner: Eisai Co., Ltd.,University of Liverpool,Liverpool School of Tropical Medicine
  • Awarded Amount: $4,335,812
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Lead Optimization
  • Disease: NTD (Chagas disease)
  • Intervention: Drug
  • RFP Year: 2019
  • Status: 
  • Project: Lead optimization of a candidate series active against Chagas Disease
  • Partner: Daiichi Sankyo, Inc.,Drugs for Neglected Diseases initiative
  • Awarded Amount: $4,318,565
Details
  • Development Stage: Preclinical
  • Current Stage: Vaccine Preclinical Development
  • Disease: NTD (Dengue)
  • Intervention: Vaccine
  • RFP Year: 2014
  • Status: 
  • Project: Development of a Live Attenuated Tetravalent Dengue Vaccine
  • Partner: The Chemo-Sero-Therapeutic Research Institute (KAKETSUKEN),Mahidol University
  • Awarded Amount: $3,450,276
Details
  • Development Stage: Preclinical
  • Current Stage: Vaccine Preclinical Development
  • Disease: NTD (Chagas disease)
  • Intervention: Vaccine
  • RFP Year: 2014
  • Status: 
  • Project: Adjuvant Technologies to Advance Chagas Disease Vaccine Development
  • Partner: Eisai Co., Ltd.,Baylor College of Medicine (BCM),Aeras,Sabin Vaccine Institute
  • Awarded Amount: $2,000,000
Details
  • Development Stage: Preclinical
  • Current Stage: Vaccine Lead Optimization
  • Disease: NTD (Leishmaniasis)
  • Intervention: Vaccine
  • RFP Year: 2015
  • Status: 
  • Project: Live attenuated prophylactic vaccine for leishmaniasis
  • Partner: Institute of Tropical Medicine (NEKKEN) Nagasaki University ,McGill University ,The Ohio State University
  • Awarded Amount: $1,832,967
Details
  • Development Stage: Preclinical
  • Current Stage: Vaccine Preclinical Development
  • Disease: NTD (Dengue)
  • Intervention: Vaccine
  • RFP Year: 2015
  • Status: 
  • Project: Preclinical development of MVDVax, a new dengue vaccine
  • Partner: Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Institut Pasteur,European Vaccine Initiative (EVI)
  • Awarded Amount: $612,902
Details
  • Development Stage: Preclinical
  • Current Stage: Vaccine Preclinical Development
  • Disease: NTD (Leishmaniasis)
  • Intervention: Vaccine
  • RFP Year: 2016
  • Status: 
  • Project: Preclinical and preparation of early clinical testing of a new vaccine candidate against cutaneous leishmaniasis
  • Partner: Nagasaki University,London School of Hygiene and Tropical Medicine(LSHTM),Mologen ,Charité –Universitätsmedizin Berlin,European Vaccine Initiative (EVI)
  • Awarded Amount: $4,096,664
Details
  • Development Stage: Preclinical
  • Current Stage: Vaccine Preclinical Development
  • Disease: NTD (Dengue)
  • Intervention: Vaccine
  • RFP Year: 2016
  • Status: 
  • Project: Development of novel dengue virus-like particle (VLP) vaccines against all four serotypes
  • Partner: Institute of Tropical Medicine (NEKKEN) Nagasaki University ,National Institute of Infectious Diseases,VLP Therapeutics
  • Awarded Amount: $986,540
Details
  • Development Stage: Preclinical
  • Current Stage: Vaccine Preclinical Development
  • Disease: NTD (Dengue)
  • Intervention: Vaccine
  • RFP Year: 2018
  • Status: 
  • Project: The development and production of cGMP lots of a novel tetravalent dengue virus-like particle (VLP) vaccine
  • Partner: Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Johns Hopkins University,Latham BioPharm Group,National Institute of Infectious Diseases,VLP Therapeutics
  • Awarded Amount: $4,422,091
Details
  • Development Stage: Preclinical
  • Current Stage: Vaccine Preclinical Development
  • Disease: NTD (Leishmaniasis)
  • Intervention: Vaccine
  • RFP Year: 2018
  • Status: 
  • Project: Live attenuated prophylactic vaccine for leishmaniasis
  • Partner: Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Gennova Biopharmaceuticals Ltd.,McGill University ,The Ohio State University
  • Awarded Amount: $3,998,989
Details
  • Development Stage: Preclinical
  • Current Stage: Vaccine Preclinical Development
  • Disease: NTD (Leishmaniasis)
  • Intervention: Vaccine
  • RFP Year: 2018
  • Status: 
  • Project: Immune therapy to prevent VL complications
  • Partner: University of Tokyo,International Center for Diarrheal Disease Research Bangladesh,Infectious Disease Research Institute
  • Awarded Amount: $558,315
Details
  • Development Stage: Preclinical
  • Current Stage: Vaccine Lead Optimization
  • Disease: NTD (Chagas disease)
  • Intervention: Vaccine
  • RFP Year: 2019
  • Status: 
  • Project: Optimization and pre-clinical development of a Trypanosoma cruzi Cyp19 knock-out strain as a live vaccine for Chagas disease.
  • Partner: Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Ohio University,The Ohio State University
  • Awarded Amount: $1,097,927
Details
  • Development Stage: Preclinical
  • Current Stage: Diagnostic Product Design
  • Disease: NTD (Leishmaniasis)
  • Intervention: Diagnostic
  • RFP Year: 2019
  • Status: 
  • Project: Production, validation and use of Leishmanin skin test (LST) for detection of Leishmania exposure and immunity
  • Partner: Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Gennova Biopharmaceuticals Ltd.,McGill University ,U.S. Food and Drug Administration,The Ohio State University
  • Awarded Amount: $2,257,699
Details
  • Development Stage: Clinical
  • Current Stage: Drug Clinical Phase2
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2013
  • Status: 
  • Project: Development of DSM265 as a long acting antimalarial compound
  • Partner: Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $2,538,796
Details
  • Development Stage: Clinical
  • Current Stage: Drug Clinical Phase1
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2014
  • Status: 
  • Project: Testing DSM265, a novel antimalarial acting through DHODH, in combination with OZ439
  • Partner: Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $1,290,883
Details
  • Development Stage: Clinical
  • Current Stage: Drug Clinical Phase2
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2015
  • Status: 
  • Project: Commercial formulation development of DSM265
  • Partner: Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $1,905,341
Details
  • Development Stage: Clinical
  • Current Stage: Drug Clinical Phase2
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2016
  • Status: 
  • Project: Phase 2 Trial of SJ733, a Novel PfATP4 Inhibitor for Malaria
  • Partner: Eisai Co., Ltd.,Medicines for Malaria Venture (MMV),University of Kentucky
  • Awarded Amount: $4,500,001
Details
  • Development Stage: Clinical
  • Current Stage: Drug Clinical Phase2
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2016
  • Status: 
  • Project: Formulation Optimization Work on DSM265
  • Partner: Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $1,589,999
Details
  • Development Stage: Clinical
  • Current Stage: Vaccine Phase1 Clinical Development
  • Disease: Malaria
  • Intervention: Vaccine
  • RFP Year: 2013
  • Status: 
  • Project: Clinical Development of BK-SE36/CpG Malaria Vaccine
  • Partner: Research Institute for Microbial Diseases (RIMD), Osaka University,Gulu University, Uganda
  • Awarded Amount: $714,500
Details
  • Development Stage: Clinical
  • Current Stage: Vaccine Phase1 Clinical Development
  • Disease: Malaria
  • Intervention: Vaccine
  • RFP Year: 2014
  • Status: 
  • Project: Clinical development of the BK-SE36 malaria vaccine candidate
  • Partner: Research Institute for Microbial Diseases (RIMD), Osaka University,Centre National de Recherche et de Formation sur le Paludisme (CNRFP),European Vaccine Initiative (EVI)
  • Awarded Amount: $999,999
Details
  • Development Stage: Clinical
  • Current Stage: Vaccine Phase1 Clinical Development
  • Disease: Malaria
  • Intervention: Vaccine
  • RFP Year: 2016
  • Status: 
  • Project: Clinical Development of BK-SE36/CpG Malaria Vaccine: safety evaluation of BK-SE36/CpG in the malaria endemic population
  • Partner: Medical Center for Translational Research (MTR), Osaka University Hospital,Institut de Recherche en Sciences de la Santé (IRSS),Nobelpharma Co., Ltd.,Research Institute for Microbial Diseases (RIMD), Osaka University,European Vaccine Initiative (EVI)
  • Awarded Amount: $2,781,588
Details
  • Development Stage: Clinical
  • Current Stage: Vaccine Phase1 Clinical Development
  • Disease: Malaria
  • Intervention: Vaccine
  • RFP Year: 2019
  • Status: 
  • Project: Preparatory phase II for the malaria vaccine candidate NPC-SE36/CpG
  • Partner: Nobelpharma Co., Ltd.,Groupe de Recherche Action en Santé (GRAS),Research Institute for Microbial Diseases (RIMD), Osaka University,European Vaccine Initiative (EVI)
  • Awarded Amount: $1,870,777
Details
  • Development Stage: Clinical
  • Current Stage: Diagnostic Product Validation
  • Disease: Malaria
  • Intervention: Diagnostic
  • RFP Year: 2015
  • Status: 
  • Project: Development of a fully automated malaria diagnostic system and field evaluation for practical use
  • Partner: Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Juntendo University,Kenya Medical Research Institute (KEMRI-CGHR),Malaria No More Japan (MNMJ),National Institute of Advanced Industrial Science and Technology,Panasonic Corporation
  • Awarded Amount: $964,500
Details
  • Development Stage: Clinical
  • Current Stage: Vaccine Phase2 Clinical Development
  • Disease: Tuberculosis
  • Intervention: Vaccine
  • RFP Year: 2015
  • Status: 
  • Project: DAR-901 whole cell booster vaccine to prevent TB infection in adolescents (“DAR-PIA”)
  • Partner: Tokyo Medical and Dental University,Muhimbili University of Health and Allied Sciences (MUHAS),Geisel School of Medicine at Dartmouth
  • Awarded Amount: $1,423,590
Details
  • Development Stage: Clinical
  • Current Stage: Diagnostic Product Validation
  • Disease: Tuberculosis
  • Intervention: Diagnostic
  • RFP Year: 2015
  • Status: 
  • Project: Highly Sensitive POC TB-LAM Rapid Diagnostic Test
  • Partner: Fujifilm Corporation ,Foundation for Innovative New Diagnostics (FIND)
  • Awarded Amount: $2,160,577
Details
  • Development Stage: Clinical
  • Current Stage: Diagnostic Product Validation
  • Disease: Tuberculosis
  • Intervention: Diagnostic
  • RFP Year: 2017
  • Status: 
  • Project: Fujifilm SILVAMP TB LAM – A Sensitive point-of-care Tuberculosis Test
  • Partner: Fujifilm Corporation ,Foundation for Innovative New Diagnostics (FIND)
  • Awarded Amount: $4,217,169
Details
  • Development Stage: Clinical
  • Current Stage: Drug Clinical Phase2
  • Disease: NTD (Chagas disease)
  • Intervention: Drug
  • RFP Year: 2013
  • Status: 
  • Project: A new treatment for Chagas disease
  • Partner: Eisai Co., Ltd.,Drugs for Neglected Diseases initiative
  • Awarded Amount: $3,840,892
Details
  • Development Stage: Clinical
  • Current Stage: Drug Clinical Phase1
  • Disease: NTD (Schistosomiasis)
  • Intervention: Drug
  • RFP Year: 2013
  • Status: 
  • Project: Development and registration of a new praziquantel pediatric formulation for the treatment of schistosomiasis
  • Partner: Astellas Pharma Inc.,Farmanguinhos,Merck KGaA,Simcyp Limited,Swiss Tropical and Public Health Institute,Lygature
  • Awarded Amount: $1,864,898
Details
  • Development Stage: Clinical
  • Current Stage: Drug Clinical Phase2
  • Disease: NTD (Schistosomiasis)
  • Intervention: Drug
  • RFP Year: 2014
  • Status: 
  • Project: Development and registration of a new praziquantel pediatric formulation for the treatment of schistosomiasis
  • Partner: Astellas Pharma Inc.,Farmanguinhos,Merck KGaA,Simcyp Limited,Swiss Tropical and Public Health Institute,Lygature
  • Awarded Amount: $4,856,513
Details
  • Development Stage: Clinical
  • Current Stage: Drug Clinical Phase3
  • Disease: NTD (Schistosomiasis)
  • Intervention: Drug
  • RFP Year: 2016
  • Status: 
  • Project: Development and registration of a new pediatric praziquantel formulation for the treatment of schistosomiasis in preschool-aged children
  • Partner: Astellas Pharma Inc.,Farmanguinhos,Merck KGaA,Schistosomiasis Control Initiative (SCI),Simcyp Limited,Swiss Tropical and Public Health Institute,Lygature
  • Awarded Amount: $4,679,698
Details
  • Development Stage: Clinical
  • Current Stage: Drug Clinical Phase2
  • Disease: NTD (Mycetoma)
  • Intervention: Drug
  • RFP Year: 2017
  • Status: 
  • Project: Mycetoma Treatment, Fosravuconazole Clinical Trial
  • Partner: Eisai Co., Ltd.,Drugs for Neglected Diseases initiative
  • Awarded Amount: $2,526,217
Details
  • Development Stage: Clinical
  • Current Stage: Drug Registration
  • Disease: NTD (Schistosomiasis)
  • Intervention: Drug
  • RFP Year: 2018
  • Status: 
  • Project: Treating schistosomiasis in preschool-aged children: development, registration and access to L-praziquantel orally disintegrating tablet formulation
  • Partner: Astellas Pharma Inc.,Farmanguinhos,Kenya Medical Research Institute (KEMRI-CGHR),Merck KGaA,Schistosomiasis Control Initiative (SCI),Swiss Tropical and Public Health Institute,Université Félix Houphouët Boigny (UFHB),Lygature
  • Awarded Amount: $4,523,295
Details